|
|
| | PGD2-inhibitor Basic information |
| Product Name: | PGD2-inhibitor | | Synonyms: | PGD2-inhibitor;PGD2-IN-1;MDK66671;PGD2-IN-1?, >98%;PGD2-inhibitor, >98%;prostaglandin D2(PGD2) inhibitor;PGD2 inhibitor 1;Benzeneacetic acid, 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-α,α-dimethyl- | | CAS: | 885066-67-1 | | MF: | C23H23Cl2N3O3 | | MW: | 460.35 | | EINECS: | | | Product Categories: | | | Mol File: | 885066-67-1.mol |  |
| | PGD2-inhibitor Chemical Properties |
| Boiling point | 682.1±65.0 °C(Predicted) | | density | 1.326±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 25 mg/mL (54.31 mM) | | form | Solid | | pka | 4.09±0.10(Predicted) | | color | White to off-white |
| | PGD2-inhibitor Usage And Synthesis |
| Biological Activity | PGD2-IN-1 is a DP receptor antagonist from patent patent WO 2006044732 A2, compound example 15 (d) with IC50 value of 0.3 nM. | | in vitro | Prostaglandin D2 (PGD2) is a major inflammatory mediator implicated in asthma and allergic rhinitis. It is largely produced as the major cyclooxygenase metabolite upon allergen-provoked degranulation from mast cells. Blockage of PGD2 using DP antagonists has been shown to be effective at alleviating the symptoms of allergic rhinitis in multiple species and more specifically has been shown to inhibit the antigen-induced nasal congestion. | | target | |
| | PGD2-inhibitor Preparation Products And Raw materials |
|